Author

Carolina Acuipil

Observed names: Acuipil, C., C. Acuipil, CAROLINA ACUIPIL

Institution: Durham Public Schools

Observed institutions: GlaxoSmithKline (United Kingdom), Universidad de Buenos Aires, Durham Public Schools

ORCID: 0009-0008-7672-3818

Observed ORCID: 0009-0008-7672-3818

OpenAlex ID: A5077601796

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

2023 · Edgar T Overton, Gary Richmond, et al. · Clinical Infectious Diseases · 157

Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study

2025 · Susan L Ford, Franco Felizarta, et al. · Clinical Infectious Diseases · 8

Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

2025 · Nilay Thakkar, Rulan Griesel, et al. · Infectious Diseases and Therapy · 5

Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083

2025 · Brett Hanscom, Mark A Marzinke, et al. · The Journal of Infectious Diseases · 4

Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1

2025 · Ronald D’Amico, Kelong Han, et al. · AIDS · 4

Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV

2025 · Nilay Thakkar, Rulan Griesel, et al. · Infectious Diseases and Therapy · 3

Distribution of NADPH-diaphorase in rat mesencephalon: A light and electron microscopical study

2002 · JUAN J. L覲EZ-COSTA, CAROLINA ACUIPIL, et al. · Biocell · 3

Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study

2024 · Landovitz, Raphael, Gao, F., et al. · Arca - Repositório Institucional da Fiocruz

Cabotégravir + rilpivirine à longue durée d'action tous les 2 mois : résultats d'ATLAS 2M à 152 semaines

2022 · J. Reynes, E. Overton, et al. · Médecine et Maladies Infectieuses Formation

Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants

2010 · J. Ambrosioni, G. Andreani, et al. · Archives of Virology

Works count: 10

Citation count: 184

H-index: 4

I10-index: 1